NewsRoom Articles - Page 2 of 243

ThursdayDec 22, 2022 9:00 am

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022 Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue Under his leadership, Flora has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide. Mr. Merchan has also spearheaded several M&As, all of which have since set the…

TuesdayDec 20, 2022 9:00 am

Cannabis Products Continue to Flourish, Showcasing Potential of Cultivator Flora Growth Corp.’s (NASDAQ: FLGC) Growing International House of Brands

Cannabis grower and brand builder Flora Growth is a rapidly growing international supplier and supply chain developer aiming to distinguish itself in a highly competitive market Following on a 604 percent YOY revenue increase for the first half of the year, Flora continues pursuing strategic acquisitions such as its recent all-stock deal for multi-national operator Franchise Global Health Flora also anticipates expanding its production facilities, adding a fourth by the end of this year that will provide the company with its first pharmaceutical formula operation for the Colombian wellness market The Franchise Global Health agreement is expected to give Flora…

ThursdayDec 15, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be equally or even more effective at lower doses than Epidiolex, one of the world’s leading anti-seizure medications and the world’s only commercially approved CBD-powered anti-seizure drug Lexaria looks to build on the findings so far…

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks) The company has also started investigating DehydraTECH-CBD as a…

WednesdayDec 07, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug The first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex The second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved…

FridayDec 02, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia

Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030 The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029 Clinical studies have established a connection between hypertension and dementia With DehydraTECH(TM)-CBD already evidencing that it can lower blood pressure and its propensity to cross the blood-brain barrier, Lexaria is investigating the potential for a positive outcome in the DEM-A22-1 study According to the World Health Organization (“WHO”), dementia is the seventh…

TuesdayNov 29, 2022 1:30 pm

Prime Harvest Inc. Positioned to Lead California’s Cannabis Market with Direct-to-Consumer Expansion

Prime Harvest is the parent company of Jaxx Cannabis, its D2C operations actively expanding throughout California Prime Harvest’s brand partners strongly positioned across multiple segments of the cannabis value chain Brand partners include Mary's Medicinals, STIIIZY, Lime Cannabis, and Tonik Revenue diversification is critical to sustainable growth in the cannabis industry, and it’s central to the strategy of Prime Harvest, a technology-focused, full-service cannabis corporation. With a strong portfolio of successful brand partners, Prime Harvest is strongly positioned to lead California’s sector through robust diversification across multiple segments of the cannabis value chain. “Our approach is to create strong alliances…

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

WednesdayNov 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

News and publishing service for CBD related companies

Contact us: 303.498.7722